翰森制药（03692）：催化因素丰富的2026年

Investment Rating - The report provides a positive outlook for Hansoh Pharmaceutical, indicating a strong performance in the second half of 2025 with revenue growth of 32% and net profit growth of 47%, exceeding market expectations by 2% and 10% respectively [4]. Core Insights - Hansoh Pharmaceutical is expected to experience significant growth in 2026, driven by the launch of innovative drugs and business development revenues. The year is characterized as a "harvest year" with multiple catalysts expected to enhance the company's pipeline value and profitability [4][7]. - Key clinical catalysts for 2026 include HS-20093 (B7H3 ADC), HS-20094 (GIP/GLP-1), and HS-10374 (TYK2), which are anticipated to provide critical clinical data and regulatory visibility [6][7]. Summary by Sections Financial Performance - In the second half of 2025, the oncology segment saw a sales increase of 49% to 5.4 billion yuan, while anti-infection products grew by 12% to 850 million yuan. However, sales in the central nervous system segment declined by 16% to 540 million yuan [5]. - Operating profit and net profit for the second half of 2025 increased by 76% and 47% respectively, reaching 22.7 billion yuan and 2.4 billion yuan [5]. Clinical Catalysts - HS-20093 is highlighted as a key catalyst in oncology, with pivotal Phase III clinical data expected to influence regulatory visibility and the value of the ADC platform. HS-20094 is noted for its potential impact on market sentiment, with detailed obesity data expected in 2026 [6]. - HS-10374 is considered an important indicator in immunology, with Phase III data for psoriasis serving as a test for the company's capabilities beyond oncology [6]. Company Overview - Hansoh Pharmaceutical is recognized as a leading R&D-driven innovative pharmaceutical company in China, focused on addressing unmet clinical needs and enhancing human health. As of June 30, 2025, the company had received approvals for seven innovative drugs and submitted four new drug applications [9].